Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
about
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingThe alphabet of intrinsic disorder: II. Various roles of glutamic acid in ordered and intrinsically disordered proteins.Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugsProcoagulant inhibitory properties of paclitaxel poliglumex.Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.Protease-activated drug development.Drug-Free Macromolecular Therapeutics--A New Paradigm in Polymeric NanomedicinesThe Acinar Cage: Basement Membranes Determine Molecule Exchange and Mechanical Stability of Human Breast Cell AciniPolymeric conjugates for drug deliveryNC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivoAntitumor activity of folate-targeted, paclitaxel-loaded polymeric micelles on a human esophageal EC9706 cancer cell line.Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates.Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatmentClinical developments in nanotechnology for cancer therapy.Polymer-drug conjugates for novel molecular targets.Cancer immunotherapy: nanodelivery approaches for immune cell targeting and trackingNanomedicine as an emerging platform for metastatic lung cancer therapy.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Dendritic polyglycerol sulfate as a novel platform for paclitaxel delivery: pitfalls of ester linkage.Particle replication in nonwetting templates nanoparticles with tumor selective alkyl silyl ether docetaxel prodrug reduces toxicity.Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer.Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure–property relationships to better defined therapeutics
P2860
Q26778234-80B701E0-8DAB-4244-A51B-4755C70DD649Q30402098-94DAA337-658F-43AE-9518-2D85484BFA00Q33380181-425375F8-3E0B-468E-9F56-30EE7760164CQ33830347-6CE9BE18-2E21-4FE5-A418-2436037D692BQ33936160-7FCCA5AD-7BF5-43CA-B14B-63B62897C472Q34665903-1C2247FF-1E2A-41A2-8258-7F49A0DFF3C9Q35646297-66E7C27B-ECDF-4BE8-961E-DDF798EFDD62Q35811508-8D59A2D9-D9F7-40ED-9E9B-14E1F00C2996Q35861726-497E8D8C-DD9E-418D-9FDC-185FC8B043D8Q35870478-F4C98244-ADA0-41BE-B5D1-A7661F8203F5Q36029175-90AAF568-5207-4478-92BA-7F300EAFD249Q36058744-F72A1EF0-2759-4406-A70B-43970C0B7381Q36119585-3DE55E7F-6415-4EFF-AD5E-6356863FA836Q36394925-8A065185-B732-47E3-B78D-59D801F1FF91Q36589127-78841867-6399-482E-ACCF-F3641EDEDC09Q37034326-FB60C969-5212-4185-A64F-B859331AE42EQ37096500-91DE88E4-D239-4767-BB41-A6CB7EB0AAD0Q37206486-7654433B-DF82-454C-82AB-C97BC5551A54Q37765187-90344F53-54B7-435D-A0AE-407BDA8C29DDQ37782076-C78F8C91-CDAC-4E9A-94B1-2B51C57ADC64Q38288055-EBBEEC76-EFB1-4B6C-A47B-8C1388E46CB9Q38463092-C4055958-CFCB-4140-97E9-EE61E07A0B27Q38577297-0AD76716-77CE-4520-9332-2A1131C248A5Q38927851-CA9D1BFD-B45F-483A-A685-7C08B5EADC92Q42109453-11859399-D06B-46DB-AEDD-71B374DB759DQ49787181-D1DCAADC-98F5-496C-A872-439112750B10Q57367046-298AEA2C-8C18-4679-866B-17453C384733
P2860
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Biological and clinical charac ...... ecular polymer-drug conjugate.
@en
type
label
Biological and clinical charac ...... ecular polymer-drug conjugate.
@en
prefLabel
Biological and clinical charac ...... ecular polymer-drug conjugate.
@en
P2093
P2860
P921
P1476
Biological and clinical charac ...... ecular polymer-drug conjugate.
@en
P2093
Fred B Oldham
Gabriella Pezzoni
Jack W Singer
Stewart D Chipman
P2860
P304
P356
10.2147/NANO.2006.1.4.375
P407
P577
2006-01-01T00:00:00Z